Chemerin-9 peptide

Chemerin-9 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

H-YFPGQFAFS-OH

H-Tyr-Phe-Pro-Gly-Gln-Phe-Ala-Phe-Ser-OH

9

95.52%

C₅₄H₆₆N₁₀O₁₃

1063.16

Synthetic

Powder

Chemerin-9 is a nonapeptide corresponding to amino acids 149-157 of the C terminus of processed chemerin, which retains most of the agonist activity of the full-size protein towards the chemokine-like receptor 1 (CMKLR1) with an EC50 of 7.1 nM. Chemerin-9 significantly suppresses TNF-α-induced mRNA expression of adhesion and pro-inflammatory molecules in human umbilical vein endothelial cells (HUVECs) and significantly attenuates TNF-α-induced adhesion of THP1 monocytes and the macrophage inflammatory phenotype. In Apoe -/- mice, a 4-week infusion of chemerin-9 significantly decreases aortic atherosclerotic lesions.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Wittamer et al (2004) The C-terminal nonapeptide of mature chemerin activates the chemerin receptor with low nanomolar potency. J Biol Chem. 279(11) 9956 PMID: 14701797
• Sato et al (2019) Chemerin-9, a potent agonist of chemerin receptor (ChemR23), prevents atherogenesis. Clin Sci (Lond). 133(16) 1779 PMID: 31399499
• Kasimu (2020) Regulatory effect of chemerin and therapeutic efficacy of chemerin‑9 in pancreatogenic diabetes mellitus. Mol Med Rep. 21(3) 981 PMID: 31922216

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.